[
    [
        {
            "time": "2018-01-02",
            "original_text": "Daily Dividend Report: BAX, JLL, JCOM, DK, LLY",
            "features": {
                "keywords": [
                    "dividend",
                    "BAX",
                    "JLL",
                    "JCOM",
                    "DK",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "real estate",
                    "communications",
                    "energy"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Daily Dividend Report: BAX, JLL, JCOM, DK, LLY",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "Keytruda: Merck’s Immuno-Oncology Blockbuster Drug in 1Q18",
            "features": {
                "keywords": [
                    "Keytruda",
                    "Merck",
                    "Immuno-Oncology",
                    "blockbuster",
                    "1Q18"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Keytruda: Merck’s Immuno-Oncology Blockbuster Drug in 1Q18",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "Merck’s Segment-Wise Performance in 1Q18",
            "features": {
                "keywords": [
                    "Merck",
                    "segment-wise",
                    "performance",
                    "1Q18"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck’s Segment-Wise Performance in 1Q18",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-01",
            "original_text": "Will Elanco’s Top-Line Growth Return in 2018?",
            "features": {
                "keywords": [
                    "Elanco",
                    "top-line",
                    "growth",
                    "2018"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Will Elanco’s Top-Line Growth Return in 2018?",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-01",
            "original_text": "Label Expansion Might Boost Cyramza’s Revenues in 2018",
            "features": {
                "keywords": [
                    "label expansion",
                    "Cyramza",
                    "revenues",
                    "2018"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Label Expansion Might Boost Cyramza’s Revenues in 2018",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]